Despite the ability of ibrutinib to disrupt CLL cell interactions within their protective niches, inhibiting BTK in NLCs may actually promote CLL cell survival, which may explain the inability of ibrutinib to overcome the protective effects provided by NLCs [47, 48]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.